Evidence map›Paper›PMID 40948808›Full record

ArticleFrontiers in neuroscience2025

Olfactory EEG based Alzheimer disease classification through transformer based feature fusion with tunable

Berke Cansiz, Hamza Osman Ilhan, Nizamettin Aydin, Gorkem Serbes

Abstract read
In one paragraph

Article in Frontiers in neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Berke CansizDepartment of Electronics and Communication Engineering, Yildiz Technical University, Istanbul, Türkiye.
Hamza Osman IlhanDepartment of Computer Engineering, Yildiz Technical University, Istanbul, Türkiye.
Nizamettin AydinDepartment of Computer Engineering, Istanbul Technical University, Istanbul, Türkiye.
Gorkem SerbesDepartment of Biomedical Engineering, Yildiz Technical University, Istanbul, Türkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Alzheimer's disease has been considered one of the most dangerous neurodegenerative health problems. This disease, which is characterized by memory loss, leads to conditions that adversely affect daily life. Early diagnosis is crucial for effective treatment and is achieved through various imaging technologies. However, these methods are quite costly and their results depend on the expertise of the specialist physician. Therefore, deep learning techniques have recently been utilized as decision support tools for Alzheimer's disease. Methods: In this research, the detection of Alzheimer's disease was investigated using a deep learning model applied to electroencephalography signals, taking advantage of olfactory memory. The dataset comprises three categories: healthy individuals, those with amnestic mild cognitive impairment, and Alzheimer's disease patients. The proposed model integrates three distinct feature types through a transformer-based fusion approach for classification. These feature vectors are derived from the Common Spatial Pattern, Covariance matrix-Tangent Space and a Tunable Q-Factor wavelet coefficient mapping. Results: The results demonstrated that subject-based classification of rose aroma attained a 93.14% accuracy using EEG-recorded olfactory memory responses. Conclusion: This output has demonstrated superiority over EEG-based results reported in the literature.

Indexed as

Alzheimer's diseasecommon spatial patterncovariance matrix-tangentelectroencephalographymild cognitive impairmentolfactory stimulationtransformer-based fusiontunable Q-factor wavelet transform

Identifiers

PMID40948808
PMCPMC12423031

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.